Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Ohio: - Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Ohio: - Research Site — Cleveland, Ohio
- Research Site — Columbus, Ohio
Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Ohio: - Site 23 — Cincinnati, Ohio
- Site 87 — Cleveland, Ohio
- Site 32 — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Ohio: - University of Cincinnati - UC Health Barrett Cancer Center — Cincinnati, Ohio
- Ohio State University, James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Kettering — Kettering, Ohio
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Miami Valley Hospital South — Centerville, Ohio
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
- Premier Blood and Cancer Center — Dayton, Ohio
- Miami Valley Hospital North — Dayton, Ohio
- Atrium Medical Center-Middletown Regional Hospital — Franklin, Ohio
- Miami Valley Cancer Care and Infusion — Greenville, Ohio
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Premier Blood and Cancer Center — Dayton, Ohio
Phase 2 Recruiting NIH
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Ohio: - Local Institution - 2112 — Canton, Ohio
- Local Institution - 2143 — Cincinnati, Ohio
- Local Institution - 2109 — Cleveland, Ohio
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Local Institution - 2119 — Toledo, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Ohio: - Research Site 138 — Canton, Ohio
- Research Site 113 — Cincinnati, Ohio
- Research Site 131 — Dayton, Ohio
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Ohio: - UH Cleveland Medical Center — Cleveland, Ohio
- Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…
Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Ohio: - The Ohio State University James Cancer Hospital & Solove Research Institute — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Ohio: - Taylor Cancer Research Center (site 204) — Maumee, Ohio
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Ohio: - Cleveland Clinic - Oncology Department — Cleveland, Ohio
Phase 2 Recruiting Industry
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conduct…
Sponsor: Tanabe Pharma America, Inc.
NCT ID: NCT06943521
Sites in Ohio: - The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Academic/Other
The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT06627270
Sites in Ohio: - Case Comprehensive Cancer Center, Cleveland Clinic Foundation — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC). The purpose of the Phase II st…
Sponsor: University of Cincinnati
NCT ID: NCT07213934
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
Phase 2 Recruiting Academic/Other
This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.
Sponsor: Sara Medek
NCT ID: NCT07497607
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio